BIIB 021

Discontinued Product

BIIB 021 (Cat. No. 4608) has been withdrawn from sale for commercial reasons.
Description: Selective Hsp90 inhibitor
Alternative Names: CNF 2024
Chemical Name: 6-Chloro-9-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-9H-purin-2-amine
Purity: ≥98% (HPLC)
Datasheet
Citations (1)
Reviews (1)
Literature (2)

Biological Activity for BIIB 021

BIIB 021 is a selective, Hsp90 competitive inhibitor (Ki = 1.7 nM). Displays no significant activity at a range of ATP-binding kinases or Na+K+ ATPase. Induces degradation of HER-2 in vitro (EC50 = 38 nM in MCF-7 cells). Inhibits growth and promotes cell death in a variety of human tumor cells. Orally bioavailable.

Technical Data for BIIB 021

M. Wt 318.76
Formula C14H15ClN6O
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 848695-25-0
PubChem ID 16736529
InChI Key QULDDKSCVCJTPV-UHFFFAOYSA-N
Smiles ClC1=C2C(N(CC3=NC=C(C)C(OC)=C3C)C=N2)=NC(N)=N1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for BIIB 021

References are publications that support the biological activity of the product.

Lundgren et al (2009) BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol.Cancer Ther. 8 921 PMID: 19372565

Yin et al (2010) BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int.J.Cancer 126 1216 PMID: 19662650

View Related Products by Target

View Related Products by Product Action

View all Hsp90 Inhibitors

Keywords: BIIB 021, BIIB 021 supplier, BIIB021, heat, shock, proteins, 90, hsp90, inhibitors, chaperones, HER-2, antitumor, antitumour, CNF2024, inhibits, orally, bioavailable, potent, selective, CNF, 2024, Hsp90, 4608, Tocris Bioscience

1 Citation for BIIB 021

Citations are publications that use Tocris products. Selected citations for BIIB 021 include:

Catherine B et al (2021) Inhibition of the NLRP3 inflammasome by HSP90 inhibitors. Immunology 162 84-91 PMID: 32954500


Reviews for BIIB 021

Average Rating: 5 (Based on 1 Review.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used BIIB 021?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


BIIB 021 induces PARP cleavage in U2OS cells.
By Anonymous on 03/25/2019
Assay Type: In Vitro
Species: Human
Cell Line/Tissue: Osteosarcoma

Human osteosarcoma, U2OS, cells were treated with BIIB 021 (1 microM) for 24 h to follow PARP cleavage using Western blot. BIIB 021 activated PARP cleavage in U2OS cells

review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cell Cycle and DNA Damage Research Product Guide

Cell Cycle and DNA Damage Research Product Guide

This product guide provides a review of the cell cycle and DNA damage research area and lists over 150 products, including research tools for:

  • Cell Cycle and Mitosis
  • DNA Damage Repair
  • Targeted Protein Degradation
  • Ubiquitin Proteasome Pathway
  • Chemotherapy Targets
Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.